Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • News
  • FDA approves AbbVie’s Parkinson’s disease therapy Juvmo
  • News

FDA approves AbbVie’s Parkinson’s disease therapy Juvmo

FDA approves AbbVie's Parkinson's therapy Juvmo and Mirum and Incyte's Atebrioz for fibrodysplasia ossificans progressiva, while Daiichi Sankyo and MSD withdraw their BLA for ifinatamab deruxtecan in small cell lung cancer.
pharminent September 28, 2026

Pharminent · Daily Brief
September 28, 2026

Regulatory & Approvals

FDA approves AbbVie’s Parkinson’s disease therapy Juvmo
AbbVie’s Parkinson’s disease therapy Juvmo has won FDA approval, the first drug from AbbVie’s $8.7 billion takeover of Cerevel two years ago.
Pharmaphorum →$ABBV

FDA approves Mirum and Incyte’s Atebrioz for FOP
The FDA approved Mirum Pharmaceuticals and Incyte’s Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva in patients aged 12 and above.
Pharmaceutical Technology →

Daiichi Sankyo, MSD withdraw ifinatamab deruxtecan BLA in small cell lung cancer
Daiichi Sankyo and Merck & Co (MSD) voluntarily withdrew their biologics license application for ifinatamab deruxtecan (I-DXd) in adult patients with extensive-stage small cell lung cancer.
Pharmaceutical Technology →$DSNKY$MRK

Clinical Data

Study finds nanopore sequencing could aid inherited muscle disease diagnosis
A new study suggests long-read ‘nanopore’ sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.
Pharmaphorum →

Forwarded this? Get your copy free
Sign up free →

Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.

Post navigation

Previous: FDA advisers back Grail’s multicancer detection blood test
Next: AstraZeneca takes 10% Summit stake in $2B deal

Related Stories

  • News

FDA declines to approve Summit’s ivonescimab in lung cancer

pharminent November 16, 2026
  • News

Lilly Wins China Approval for Oral GLP-1 Weight Loss Drug

pharminent November 13, 2026
  • News

Blackstone to fund Pfizer’s monthly GLP-1 with up to $1.5B

pharminent November 12, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.